GAPS IN EVIDENCE AND ROLE OF DIRECT ORAL ANTICOAGULANTS

Authors

  • João Rocha Neves Department of Biomedicine - Unity of Anatomy, Faculdade de Medicina da Univ. do Porto, Portugal; Department of Angiology and Vascular Surgery, Centro Hospitalar Univ. de São João, Porto, Portugal; Department of Surgery and Physiology, Faculdade de Medicina da Univ. do Porto, Portugal

DOI:

https://doi.org/10.48729/pjctvs.54

Downloads

Download data is not yet available.

References

Antunes L. New oral anticoagulants (NOACs) are the gold standard in Venous Thromboembolism. Rev Port Cir Cardiotorac Vasc. 2020;27(1)

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-23.

Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019;173:158-63.

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-14.

Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid

syndrome. Blood. 2018;132(13):1365-71.

Downloads

Published

30-03-2020

How to Cite

1.
Rocha Neves J. GAPS IN EVIDENCE AND ROLE OF DIRECT ORAL ANTICOAGULANTS. Rev Port Cir Cardiotorac Vasc [Internet]. 2020 Mar. 30 [cited 2024 May 21];27(1):13. Available from: https://pjctvs.com/index.php/journal/article/view/54

Issue

Section

Editorial Comment